Astellas Pharma (ALPMY) Expected to Announce Quarterly Earnings on Monday

Astellas Pharma (OTCMKTS:ALPMY) is projected to announce its resultson Monday, April 27th. Analysts expect the company to announce earnings of $0.1775 per share and revenue of $3.2836 billion for the quarter.

Astellas Pharma (OTCMKTS:ALPMY) last issued its quarterly earnings results on Wednesday, February 4th. The company reported $0.44 earnings per share for the quarter, beating analysts’ consensus estimates of $0.29 by $0.15. Astellas Pharma had a net margin of 15.63% and a return on equity of 23.62%. The firm had revenue of $3.67 billion during the quarter, compared to the consensus estimate of $3.21 billion. On average, analysts expect Astellas Pharma to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Astellas Pharma Price Performance

Shares of Astellas Pharma stock opened at $15.43 on Friday. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.09 and a quick ratio of 0.84. Astellas Pharma has a fifty-two week low of $8.97 and a fifty-two week high of $17.35. The firm has a fifty day moving average price of $15.81 and a two-hundred day moving average price of $13.89. The company has a market cap of $27.92 billion, a PE ratio of 12.97 and a beta of 0.17.

Analysts Set New Price Targets

A number of analysts have weighed in on ALPMY shares. Citigroup downgraded shares of Astellas Pharma from a “strong-buy” rating to a “hold” rating in a report on Monday, January 19th. Smbc Nikko Sec. raised shares of Astellas Pharma to a “hold” rating in a report on Monday, February 16th. Finally, Jefferies Financial Group raised shares of Astellas Pharma from a “hold” rating to a “strong-buy” rating in a report on Tuesday, March 24th. One analyst has rated the stock with a Strong Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold”.

About Astellas Pharma

Astellas Pharma Inc is a Tokyo-based, global pharmaceutical company traded in the United States as an American Depositary Receipt on the OTC Markets under the symbol ALPMY. The company focuses on discovering, developing and marketing prescription medicines in key therapeutic areas, including oncology, urology, immunology, neuroscience and cardiovascular/metabolic diseases. Astellas seeks to bring innovative treatments to market by combining internal research capabilities with external partnerships and collaborative agreements around the world.

Core products in Astellas’ portfolio include the immunosuppressant Prograf (tacrolimus), the overactive bladder treatments Vesicare (solifenacin) and Myrbetriq (mirabegron), and the prostate cancer therapy Xtandi (enzalutamide).